scholarly journals Dual-Modality Positron Emission Tomography/Optical Image-Guided Photodynamic Cancer Therapy with Chlorin e6-Containing Nanomicelles

ACS Nano ◽  
2016 ◽  
Vol 10 (8) ◽  
pp. 7721-7730 ◽  
Author(s):  
Liang Cheng ◽  
Anyanee Kamkaew ◽  
Haiyan Sun ◽  
Dawei Jiang ◽  
Hector F. Valdovinos ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Cancer Therapy ◽  
Optical Image ◽  
Emission Tomography ◽  
Chlorin E6 ◽  
Dual Modality ◽  
Image Guided ◽  
Positron Emission ◽  
Photodynamic Cancer Therapy

scholarly journals Chelator-Free 64Cu-Integrated Gold Nanomaterials for Positron Emission Tomography Imaging Guided Photothermal Cancer Therapy

ACS Nano ◽  
2014 ◽  
Vol 8 (8) ◽  
pp. 8438-8446 ◽  
Author(s):  
Xiaolian Sun ◽  
Xinglu Huang ◽  
Xuefeng Yan ◽  
Yu Wang ◽  
Jinxia Guo ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Cancer Therapy ◽  
Positron Emission Tomography Imaging ◽  
Emission Tomography ◽  
Tomography Imaging ◽  
Positron Emission ◽  
Gold Nanomaterials

Rapid aqueous [18F]-labeling of a bodipy dye for positron emission tomography/fluorescence dual modality imaging

2011 ◽  
Vol 47 (33) ◽  
pp. 9324 ◽  
Author(s):  
Zibo Li ◽  
Tzu-Pin Lin ◽  
Shuanglong Liu ◽  
Chiun-Wei Huang ◽  
Todd W. Hudnall ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Emission Tomography ◽  
Dual Modality ◽  
Positron Emission ◽  
Dual Modality Imaging

scholarly journals Positron Emission Tomography for Response Evaluation in Microenvironment-Targeted Anti-Cancer Therapy

Biomedicines ◽  
2020 ◽  
Vol 8 (9) ◽  
pp. 371
Author(s):  
Noboru Oriuchi ◽  
Shigeyasu Sugawara ◽  
Tohru Shiga
Keyword(s):  
Positron Emission Tomography ◽  
Tumor Microenvironment ◽  
Cancer Therapy ◽  
Fdg Pet ◽  
Cell Tracking ◽  
Therapeutic Response ◽  
Tumor Response ◽  
Checkpoint Inhibitors ◽  
Emission Tomography ◽  
Positron Emission

Therapeutic response is evaluated using the diameter of tumors and quantitative parameters of 2-[18F] fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET). Tumor response to molecular-targeted drugs and immune checkpoint inhibitors is different from conventional chemotherapy in terms of temporal metabolic alteration and morphological change after the therapy. Cancer stem cells, immunologically competent cells, and metabolism of cancer are considered targets of novel therapy. Accumulation of FDG reflects the glucose metabolism of cancer cells as well as immune cells in the tumor microenvironment, which differs among patients according to the individual immune function; however, FDG-PET could evaluate the viability of the tumor as a whole. On the other hand, specific imaging and cell tracking of cancer cell or immunological cell subsets does not elucidate tumor response in a complexed interaction in the tumor microenvironment. Considering tumor heterogeneity and individual variation in therapeutic response, a radiomics approach with quantitative features of multimodal images and deep learning algorithm with reference to pathologic and genetic data has the potential to improve response assessment for emerging cancer therapy.

Sign in / Sign up

Export Citation Format

Share Document